Nancy C Raymond1, Jon E Grant, Eli Coleman. 1. Department of Psychiatry, University of Minnesota Medical School, 2450 Riverside Avenue, Minneapolis, MN 55454, USA. raymo002@umn.edu
Abstract
BACKGROUND: Compulsive sexual behavior (CSB) is generally characterized by recurrent and intense sexually arousing fantasies, sexual urges, and behaviors, which cause individuals distress or impair daily functioning. Descriptive studies of individuals with paraphilic and nonparaphilic CSB indicate that they experience urges to engage in problematic sexual behavior. The opiate antagonist naltrexone has been successfully used to treat a number of disorders in which urges to engage in problematic behavior are a central feature, such as alcoholism. We hypothesized that naltrexone would reduce the urges and behaviors associated with CSB. METHODS: Records of 19 male patients with CSB who were treated with naltrexone at an outpatient adult sexual health clinic were retrospectively reviewed. RESULTS: Nearly all patients were already taking other psychotropic medications when naltrexone was initiated. Seventeen (89%) of the 19 patients reported a reduction in CSB symptoms when taking naltrexone for a period ranging from 2 months to 2.3 years, as judged by Clinical Global Impression scores of 1 or 2, indicating "very much improved" or "much improved." Five (26%) of the 19 patients chose to discontinue the medication. CONCLUSIONS: Naltrexone may be a useful adjunctive treatment for CSB.
BACKGROUND:Compulsive sexual behavior (CSB) is generally characterized by recurrent and intense sexually arousing fantasies, sexual urges, and behaviors, which cause individuals distress or impair daily functioning. Descriptive studies of individuals with paraphilic and nonparaphilic CSB indicate that they experience urges to engage in problematic sexual behavior. The opiate antagonist naltrexone has been successfully used to treat a number of disorders in which urges to engage in problematic behavior are a central feature, such as alcoholism. We hypothesized that naltrexone would reduce the urges and behaviors associated with CSB. METHODS: Records of 19 male patients with CSB who were treated with naltrexone at an outpatient adult sexual health clinic were retrospectively reviewed. RESULTS: Nearly all patients were already taking other psychotropic medications when naltrexone was initiated. Seventeen (89%) of the 19 patients reported a reduction in CSB symptoms when taking naltrexone for a period ranging from 2 months to 2.3 years, as judged by Clinical Global Impression scores of 1 or 2, indicating "very much improved" or "much improved." Five (26%) of the 19 patients chose to discontinue the medication. CONCLUSIONS:Naltrexone may be a useful adjunctive treatment for CSB.
Authors: Phillip O Coffin; Glenn-Milo Santos; Jaclyn Hern; Eric Vittinghoff; Deirdre Santos; Tim Matheson; Grant Colfax; Steven L Batki Journal: Addiction Date: 2017-08-29 Impact factor: 6.526
Authors: Milky Kohno; Laura E Dennis; Holly McCready; Daniel L Schwartz; William F Hoffman; P Todd Korthuis Journal: Drug Alcohol Depend Date: 2018-09-21 Impact factor: 4.492
Authors: Michael H Miner; Rebecca Swinburne Romine; Nancy Raymond; Erick Janssen; Angus MacDonald; Eli Coleman Journal: J Sex Med Date: 2016-07-30 Impact factor: 3.802
Authors: Glenn-Milo Santos; Phillip Coffin; Deirdre Santos; Shannon Huffaker; Tim Matheson; Jason Euren; Anna DeMartini; Christopher Rowe; Judith A Hahn; David Vlahov; Eric Vittinghoff; Steven L Batki Journal: J Acquir Immune Defic Syndr Date: 2016-05-01 Impact factor: 3.731